Positive

From NASDAQ.: 2024-12-09 20:38:12

Genentech presented new data on its CD20xCD3 T-cell-engaging bispecific antibody program at the ASH Annual Meeting. Data showed benefits of fixed-duration Columvi and Lunsumio for various lymphomas, with durable remissions beyond treatment. Long-term data from NP30179 study of Columvi in R/R LBCL patients showed 40% achieved CR with a median duration of 29.8 months. Four-year data from GO29781 study of Lunsumio in R/R FL patients showed long-lasting remissions, with ORR of 77.8% and CR rate of 60%. Both studies demonstrated B-cell level restoration after treatment, supporting fixed-duration approach for immune system recovery.



Read more at NASDAQ.: Genentech’s Columvi And Lunsumio Data Highlight Potential To Improve Lymphoma Outcomes